The <em>Zaltrap</em> Price Debate: Less Than Meets The Eye

The Zaltrap Price Debate: Less Than Meets The Eye

20 Nov 2012

• By Michael McCaughan

Sanofi is responding to critics of the Zaltrap price with a 50% discount. Is this a “watershed” moment for cancer drug prices? Probably not. The real test will come when payors resist a price on a drug with a proven therapeutic advantage – and when the drug really matters to the sponsor.

It is not often that a pharmaceutical company finds itself negotiating a 50% discount via the editorial pages of the New York Times.

That is what happened to Sanofi and Regeneron Pharmaceuticals Inc., however, with the newly approved colorectal cancer therapy...